title: Reasoning of an anomaly: residual block after sugammadex.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Naguib
authors.forename: Sorin J
authors.initials: SJ
authors.lastname: Brull
authors.forename: Hal R
authors.initials: HR
authors.lastname: Arkes
mesh_terms: D000732:Androstanols / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D018908:Muscle Weakness / Q000517:prevention & control*; D009388:Neostigmine / Q000627:therapeutic use*; D019148:Neuromuscular Blockade / Q000379:methods*; D009469:Neuromuscular Junction / Q000187:drug effects*; D061886:Neuromuscular Monitoring; D003473:Neuromuscular Nondepolarizing Agents / Q000627:therapeutic use*; D000077123:Rocuronium; D000077122:Sugammadex; D047408:gamma-Cyclodextrins / Q000627:therapeutic use*
chemical_list: D000732:Androstanols; D002800:Cholinesterase Inhibitors; D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D009388:Neostigmine; D000077123:Rocuronium